

## Skeletal response to insulin in the naturally occurring type 1 diabetes mellitus mouse model

Manisha Dixit<sup>1</sup>, Zhongbo Liu<sup>1</sup>, Sher-Bahadur Poudel<sup>1</sup>, Gozde Yildirim<sup>1</sup>, Yanjiao Zhang Zhang<sup>1</sup>, Shilpa Mehta<sup>1</sup>, Omer Murik<sup>2</sup>, Geona Altarescu<sup>2</sup>, Yoshifumi Kobayashi<sup>3</sup>, Emi Shimizu<sup>3</sup>, Mitchell B Schaffler<sup>4</sup>, Shoshana Yakar<sup>1</sup>

<sup>1</sup>David B. Kriser Dental Center, Department of Molecular Pathobiology New York University College of Dentistry New York, NY 10010-4086

<sup>2</sup>Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel.

<sup>3</sup>Oral Biology Department, Rutgers School of Dental Medicine, 110 Bergen Street, Newark, NJ, USA.

<sup>4</sup>Department of Biomedical Engineering, City College of New York, 160 Convent Avenue, New York, NY, 10031, USA

### Supplements;

#### Supplemental table 1: Antibodies

Antibody	Company	Catalog no	Dilution used
Cathepsin K antibody	Abcam	ab19027	1:200
pAKT(phospho Ser473) antibody	Genetex	89304-112	1:50
Glut1 antibody	Thermofisher scientific	PA1-46152	1:200
Glut4 antibody	Biogenesis	4670-1704	1:500
PDK4 antibody	Thermofisher scientific	12949-1-AP	1:50
Sclerostin antibody	R & D systems	AF1589	1:12
FGF23 antibody	R & D systems	MAB26291	1:100
Donkey Anti-Goat IgG H&L (HRP)	Abcam	ab97110	1:200
VECTASTAIN® ABC Kit (Rabbit IgG)	Vector labs	PK-4001	NA


#### Supplemental table 2: qPCR primer sequences

Gene	Forward primer	Reverse primer
Osteocyte markers		
<b>Phex</b>	GAAAGGGGACCAACCGAGG	AACTTAGGAGACCTTGACTCACT
<b>SOST</b>	AGCCTTCAGGAATGATGCCAC	CTTTGGCGTCATAGGGATGGT
<b>DMP-1</b>	TTCGCTGAGGTTTTGACCTT	TTGGGATGCGATTCTCTAC
<b>FGF-23</b>	ATGCTAGGGACCTGCCTTAGA	AGCCAAGCAATGGGGAAGTG
<b>Pdnp</b>	ACCGTGCCAGTGTGTTCTG	AGCACCTGTGGTTGTTATTTGT
<b>MEPE</b>	GTCTGTTGGACTGCTCCTCTT	CACCGTGGGATCAGGATACA
<b>RANKL</b>	CAGCATCGCTCTGTTCTGTGA	CTGCGTTTTTCATGGAGTCTCA
<b>OPG</b>	ACCCAGAAACTGGTCATCAGC	CTGCAATACACACTCATCACT

**Supplement Table 3:** mCT analysis of the osseous system of NOR, non-diabetic (ND), diabetic (D) and insulin treated (In) NOD mice. Data presented as mean $\pm$ -SD, one-way ANOVA with  $p < 0.05$  was considered significant. Comparisons that were insignificant are labeled NS.

	NOR	Non-diabetic NOD (ND)	Diabetic NOD (D)	Insulin treated NOD (In)	Significance
Sample size	10	26	19	14	Presented $p < 0.05$
<b>Femur mid-diaphysis, cortical bone parameters:</b>					
BV/TV, %	50.039 $\pm$ 0.544	57.268 $\pm$ 0.409	53.064 $\pm$ 0.921	56.237 $\pm$ 0.907	NOR vs ND NOR vs D NOR vs In ND vs D
T.Ar, mm <sup>2</sup>	1.431 $\pm$ 0.029	1.416 $\pm$ 0.016	1.346 $\pm$ 0.014	1.372 $\pm$ 0.027	NOR vs D ND vs D
B.Ar, mm <sup>2</sup>	0.716 $\pm$ 0.018	0.811 $\pm$ 0.010	0.715 $\pm$ 0.016	0.771 $\pm$ 0.016	NOR vs ND ND vs D
M.Ar, mm <sup>2</sup>	0.714 $\pm$ 0.014	0.605 $\pm$ 0.009	0.631 $\pm$ 0.013	0.601 $\pm$ 0.019	NOR vs ND NOR vs D NOR vs In
Cs.Th, mm	0.183 $\pm$ 0.003	0.212 $\pm$ 0.002	0.189 $\pm$ 0.004	0.205 $\pm$ 0.004	NOR vs ND NOR vs In ND vs D D vs In
J <sub>0</sub> , 1/mm <sup>4</sup>	0.251 $\pm$ 0.011	0.273 $\pm$ 0.006	0.234 $\pm$ 0.006	0.252 $\pm$ 0.009	NOR vs ND ND vs D
Length (Le), mm	15.648 $\pm$ 0.127	15.815 $\pm$ 0.127	15.316 $\pm$ 0.128	15.857 $\pm$ 0.065	NS
Robustness (Le/T.Ar)	0.091 $\pm$ 0.002	0.090 $\pm$ 0.001	0.088 $\pm$ 0.001	0.087 $\pm$ 0.002	NS
BMD, g/cc	1.337 $\pm$ 0.004	1.338 $\pm$ 0.005	1.348 $\pm$ 0.007	1.328 $\pm$ 0.006	NS
<b>Femur distal metaphysis, trabecular bone parameters:</b>					
BV/TV, %	6.387 $\pm$ 0.402	6.812 $\pm$ 0.719	5.818 $\pm$ 0.514	5.194 $\pm$ 0.883	NS
Tb.Th, mm	0.057 $\pm$ 0.001	0.064 $\pm$ 0.001	0.053 $\pm$ 0.002	0.060 $\pm$ 0.002	NOR vs ND ND vs D D vs In
Tb.Sp, mm	0.452 $\pm$ 0.016	0.589 $\pm$ 0.030	0.549 $\pm$ 0.024	0.634 $\pm$ 0.031	NOR vs ND NOR vs In
Tb.N, 1/mm	1.122 $\pm$ 0.061	1.053 $\pm$ 0.104	1.097 $\pm$ 0.094	0.843 $\pm$ 0.123	NS
BMD, g/cc	0.123 $\pm$ 0.005	0.112 $\pm$ 0.009	0.112 $\pm$ 0.007	0.097 $\pm$ 0.013	NS
<b>Lumbar Skeleton (L5):</b>					
Sample size	7	6	6	6	
BV/TV, %	20.216 $\pm$ 1.030	23.578 $\pm$ 1.002	16.447 $\pm$ 1.013	15.908 $\pm$ 2.014	ND vs D ND vs In
Tb.Th, mm	0.059 $\pm$ 0.001	0.074 $\pm$ 0.002	0.057 $\pm$ 0.002	0.061 $\pm$ 0.002	NOR vs ND ND vs D ND vs In
Tb.Sp, mm	0.259 $\pm$ 0.009	0.275 $\pm$ 0.009	0.276 $\pm$ 0.007	0.315 $\pm$ 0.017	NOR vs In
Tb.N, 1/mm	3.390 $\pm$ 0.140	3.182 $\pm$ 0.076	2.881 $\pm$ 0.071	2.569 $\pm$ 0.207	NS
BMD, g/cc	0.449 $\pm$ 0.017	0.533 $\pm$ 0.019	0.375 $\pm$ 0.018	0.386 $\pm$ 0.032	ND vs D ND vs In
<b>Alveolar Bone (mandible, between 1<sup>st</sup> and 2<sup>nd</sup> Molars)</b>					
Sample size	10	26	21	10	
BV/TV, %	52.397 $\pm$ 2.387	55.115 $\pm$ 3.067	39.636 $\pm$ 5.035	62.433 $\pm$ 3.101	NOR vs ND NOR vs D NOR vs In ND vs D D vs In
Tb.Th, mm	0.095 $\pm$ 0.004	0.110 $\pm$ 0.005	0.086 $\pm$ 0.008	0.119 $\pm$ 0.004	NOR vs ND NOR vs In
Tb.Sp, mm	0.085 $\pm$ 0.005	0.128 $\pm$ 0.006	0.145 $\pm$ 0.005	0.105 $\pm$ 0.011	NS
Tb.N, 1/mm	5.493 $\pm$ 0.149	4.991 $\pm$ 0.235	4.482 $\pm$ 0.235	5.237 $\pm$ 0.108	NOR vs D
BMD, g/cc	1.260 $\pm$ 0.013	1.419 $\pm$ 0.027	1.294 $\pm$ 0.043	1.299 $\pm$ 0.022	NOR vs ND ND vs D ND vs In

**Supplement Figure 1: Gene expression of osteogenic markers at the femur diaphysis, and alveolar bone of the mandible.** (A) Expression of osteocyte markers at femur diaphysis. (B) Expression of mature osteoblast and osteocyte markers in alveolar bone. (C) Expression of osteoclast markers in alveolar bone.



**Supplement Figure 2: Diabetic NOD mice show alterations in the expression of GLUT1, PDK4, and p-AKT and GLUT4. GLUT1 (A), PDK4 (B), (C) pAKT, and (D) GLUT4 positive osteocytes in cancellous bone of the L5 vertebra. Representative sections from ND-NOD, D-NOD and In-NOD groups, quantifications are provided in Figure 7.**

**supplement 2**

